Hormetic Stress Biohacking Type 1 Diabetes CGM

Image
Photo: Unsplash.com Medical Disclaimer : The content on this blog is purely for informational purposes only. For medical advice, diagnosis and treatment, consult your doctor. The ultimate goal for anyone living with Type 1 Diabetes (T1D) is stability. You want fewer spikes, fewer crashes, and more time spent in your target blood sugar range. Read more on blood sugar spike . For years, standard medical advice focused purely on matching insulin doses to carbohydrate intake. While this foundational math is necessary, it often leaves people riding a frustrating blood sugar roller coaster. Today, a new wave of tech-savvy individuals is looking beyond the traditional playbook. They are combining the principles of biohacking, the physiological benefits of hormetic stress, and the real-time data of Continuous Glucose Monitors (CGMs) to transform how they manage their health. This approach does not replace insulin. Instead, it aims to make the body more resilient, predictable, and res...

FDA Approves Drug to Improve Functional Capacity and Symptoms in Adults with Rare Inherited Heart Condition

 The U.S. Food and Drug Administration (FDA) approved Myqorzo (aficamten) tablets to treat adults with symptoms obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

Symptomatic oHCM is an inherited condition where patients have thickened heart muscle and reduced blood flow from the left side of the heart to the rest of the body, causing symptoms such as shortness of breath, fatigue, and potentially life-threatening cardiac events.

The effectiveness and safety of Myqorzo were studied in 282 adults with symptomatic oHCM randomly assigned to receive Myqorzo or placebo for 24 weeks.

At the end of the study, participants receiving Myqorzo had an increase in exercise capacity measured by peak oxygen uptake compared to no change in exercise capacity among those receiving placebo. Also, 59 percent of participants receiving Myqorzo experienced an improvement in physical activity limitations (measured using the New York Heart Association Classification system) compared to 24 percent of individual receiving placebo.

Myqorzo reduces contraction of the heart muscle which can cause heart failure. Because of the risk for heart failure, patients treated with Myqorzo must be monitored with echocardiogram, an imagery test that shows how well the heart is working. Because of the heart failure risk and need for monitoring, Myqorzo is only available through restricted program called the Myqorzo Risk Evaluation and Mitigation Strategy (REMS).

Patients must also avoid certain prescription medicines that interfere with the metabolism (breakdown) of Myqorzo.

Myqorzo received Orphan Drug Designation and Breakthrough Therapy Designation for this indication.


Comments

Popular posts from this blog

The Impressive Health Benefits of Pumpkin Seeds

The Grave Consequences of Attacking Health Sites in Iran

Why Gastric Ulcer Patients Should Avoid Tomatoes and Tomato-Based Products